Evidence map›Paper›PMID 39946406›Full record

ArticlePloS one2025

Understanding the aliya pulsed electric field dose-response relationship: Implications for ablation size, thermal load, and immune response in an orthotopic murine breast cancer model.

Ebtesam H O Nafie, Chiara Pastori, Rupsa Acharya, Rosa Kaviani, David Hunter, Waleed Shalaby, William S Krimsky, Robert E Neal

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ebtesam H O NafieGalvanize Therapeutics, Redwood City, CA, United States of America.ORCID 0000-0002-0604-6689
Chiara PastoriGalvanize Therapeutics, Redwood City, CA, United States of America.
Rupsa AcharyaGalvanize Therapeutics, Redwood City, CA, United States of America.
Rosa KavianiGalvanize Therapeutics, Redwood City, CA, United States of America.
David HunterGalvanize Therapeutics, Redwood City, CA, United States of America.
Waleed ShalabyGalvanize Therapeutics, Redwood City, CA, United States of America.
William S KrimskyGalvanize Therapeutics, Redwood City, CA, United States of America.
Robert E NealGalvanize Therapeutics, Redwood City, CA, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aliya®Pulsed Electric Field (PEF) technology is an emerging strategy in the field of cancer treatment, offering a novel approach to ablation therapy that does not rely on thermal mechanisms. By employing a multi-stage experimental setup, including potato tuber, porcine liver, and murine breast cancer models, we explored the dose-response relationship on ablation and immune modulation by varying the pulse packets delivered from 20 to 100. The biologic response observed with 60 packets represented a minimum effective dose yielding reproducible ablation parameters, immune response, and efficacy which could be augmented with immune checkpoint blockade. This pre-clinical analysis provides a first step toward understanding the therapeutic index for PEF technology beyond ablation, a consideration that will require robust clinical validation in well-designed prospective studies.

Indexed as

Breast NeoplasmsMammary Neoplasms, ExperimentalAnimalsCell Line, TumorDisease Models, AnimalFemaleMiceSwine

Identifiers

PMID39946406
PMCPMC11824980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.